This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
One week left to submit AST Board nominations
AST
There is just one week left to submit your nomination for the 2015 AST Board of Directors. Completed nominations must be submitted by 5 p.m. EST on Friday, Nov. 14, 2014. Qualified candidates must have had significant involvement in and service to the AST, demonstrated ability to think strategically, and have knowledge of or experience with governance. Click here for complete nomination requirements, or to submit a nomination.
|
|
Share this article:
    |
|
Vaccine Updates in SOT – Free webinar on Nov. 8
AST
Join Dr. Deepali Kumar and Dr. Lara Danziger-Isakov at 2 p.m. EST on Nov. 18 to learn the current recommendations for vaccination and the latest innovative research. Register today at www.myAST.org/T3 – it's free for AST members and only $25 for non-members.
Learning objectives:
- Explore current pre- and post-transplant vaccination recommendations for pediatric and adult transplant candidates/recipients.
- Appraise recent vaccination studies in transplantation with a focus on live-vaccines and more recently approved vaccinations.
- Identify new opportunities for vaccination in transplantation that are emerging.
|
UPCOMING EVENTS IN TRANSPLANTATION
|
There's still time to submit your abstract for CEOT
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona
Due to technical difficulties experienced last weekend which inadvertently closed the collection site, the CEOT abstract submission site will remain open until Wednesday, Nov. 12. AST sincerely apologies for any inconvenience. Don't miss out on the opportunity to share your research with experts in transplantation. Submit your basic, clinical or translational abstract on any transplantation or immunology topic by Nov. 3. The AST will award a limited number of Young Innovator Award travel grants to the highest scoring abstracts submitted by emerging professionals in transplantation.
Click here to register for CEOT 2015 and take advantage of early registration discounted rates! Or, learn more about this engaging meeting and view the preliminary program here.
|
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study
American Journal of Transplantation
One hundred ninety-seven patients received anti-T-lymphocyte globulins Fresenius, mycophenolate mofetil and delayed cyclosporine, and were randomized to ≥6-month corticosteroids (+CS; n = 99) or no CS (−CS; n = 98). One- and five-year actual graft survival (censored for death) was 93.2 percent and 86.4 percent in the +CS group versus 94.9 percent and 89.8 percent in the −CS group (5-year follow-up, p = 0.487). Freedom from clinical rejection was 86.9 percent and 81.8 percent versus 74.5 percent and 74.5 percent (p = 0.144), respectively, at 1 and 5 years; 5-year freedom from biopsy-proven rejection was 88.9 percent versus 83.7 percent (p = 0.227).
Risk factors for early and late biliary complications in pediatric liver transplantation
Pediatric Transplantation
BC are a common source of morbidity after pediatric LT. Knowledge about risk factors may help to reduce their incidence. Retrospective analysis of BC in 116 pediatric patients (123 LT) (single institution, 05/1990–12/2011, medium follow-up 7.9 yr). One-, five-, and 10-yr survival was 91.1 percent, no patient died of BC. Prevalence and risk factors for anastomotic and intrahepatic BC were examined. There were 29 BC in 123 LT (23.6 percent), with three main categories: 10 (8.1 percent) primary anastomotic strictures, eight (6.5 percent) anastomotic leaks, and three (2.4 percent) intrahepatic strictures.
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation
Kidney International
This study has analyzed the relationship between donor mismatches at each HLA locus and development of HLA locus–specific antibodies in patients listed for repeat transplantation. HLA antibody screening was undertaken using single-antigen beads in 131 kidney transplant recipients returning to the transplant waiting list following first graft failure. The number of HLA mismatches and the calculated reaction frequency of antibody reactivity against 10,000 consecutive deceased organ donors were determined for each HLA locus.
Preparing for the inevitable: The death of a living liver donor
Liver Transplantation
Living donor liver transplantation (LDLT) has evolved into a valuable tool for alleviating the shortage of donor organs. It represents an important option for many patients who have little or no chance of receiving an organ from a deceased donor. However, LDLT is associated with a low but finite and well-documented risk of donor morbidity and mortality. It is asserted that a donor death is an inevitable event for LDLT programs.
Extracorporeal membrane oxygenation support after pediatric orthotopic heart transplantation
Pediatric Transplantation
Mechanical circulatory support has been used for more than 30 years to allow the heart to recover from ischemia and injury. There are limited pediatric data, however, on the efficacy of ECMO in the setting of post-transplantation support for primary graft dysfunction or rejection. Data from all patients at our university-affiliated, tertiary care children's hospital who underwent OHT between 1998 and 2010 and required subsequent ECMO support were analyzed.
A struggle to survive: The experience of awaiting pediatric heart transplantation
Pediatric Transplantation
Despite the establishment of heart transplantation as a life-saving therapy for children and adolescents, little research has focused on the biopsychosocial impact of the transplant process. Few studies have captured the subjective experiences of young heart transplant recipients. This study examined the experiences and perspectives of children and adolescents during the pretransplant phase of waiting for a donor organ.
Interleukin-2 receptor antagonists for pediatric liver transplant recipients: A systematic review and meta-analysis of controlled studies
Pediatric Transplantation
IL-2RA are frequently used as induction therapy in liver transplant recipients to decrease the risk of AR while allowing the reduction of concomitant immunosuppression. The exact association with the use of IL-2RA, however, is uncertain. We performed a systematic literature search for relevant studies. Random effects models were used to assess the incidence of AR, steroid-resistant rejection, graft loss, patient death, and adverse drug reaction, with or without IL-2RA. Six studies (two randomized and four non-randomized) met the eligibility criteria.
Missed last week's issue? See which articles your colleagues read most.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
